Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations

Overview

The aim of the study is to evaluate the efficacy and safety of sirolimus (oral form), to decrease the volume and symptoms due to superficial arteriovenous malformations (AVM). Sirolimus has properties that reduce the activity of the immune system (immunosuppressant), to fight against the proliferation of cancer cells (anti- tumor) and also reduce the proliferation of blood vessels (anti -vascular). Sirolimus is primarily used in transplant patients to prevent organ transplant rejection. Many animal and laboratory studies were carried out and demonstrate in particular the activity of sirolimus on vessels. It is this anti- vascular effect that could help treat arteriovenous malformations.

Full Title of Study: “Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous Malformations”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 2024

Detailed Description

Anti-proliferative and anti-angiogenic properties of Sirolimus (Rapamycin®) are the basis of the rationale to use it in the treatment of arteriovenous malformations, for which the pathophysiology remains poorly understood. The interest of this class of drug is that inhibition of mTOR (mammalian target of rapamycin) may also block growth and / or angiogenic factors (other than VEGF) involved in the development of AVM. More specifically anti-VEGF drugs does not have that potential.

Interventions

  • Drug: Sirolimus
    • For patients with swallowing problems, and for children under 6 years and / or who have an inability to swallow tablets, the 1mg/ml solution form should be used.

Arms, Groups and Cohorts

  • Experimental: Sirolimus treatment
    • Patients will receive sirolimus (Rapamune). The dose should be adjusted to obtain a residual plasma rate of 8 to 12 ng/ml in 4 weeks. This serum level will be maintained throughout the duration of the study in the absence of side effects. In case of intolerance that do not justify the discontinuation of treatment, the dose may be reduced by maintaining a serum level greater than 3 ng/ml. The starting dose will be 2 mg per day, and will be adapted every week for one month. The preferred dosage form is tablet form. To prevent common side effects in early treatment, corticosteroids based prednisolone (SOLUPRED) will be established at a dose of 0.5 mg/ kg/day for the first week of treatment.

Clinical Trial Outcome Measures

Primary Measures

  • Treatment efficacy at M12
    • Time Frame: After 12 months of treatment
    • The efficacy of treatment is a composite criteria based on: The proportion of patients with no evolution of the AVM during the study period, The proportion of patients with a reduction in tumor volume of the AVM at least 30% of CT Angiography (CTA) criteria during the first year of the study (comparison of the volume of the AVM a year versus pre-inclusion).

Secondary Measures

  • Treatment efficacy at M3
    • Time Frame: After 3 months of treatment
  • Treatment efficacy at M6
    • Time Frame: After 6 months of treatment
  • Treatment efficacy at M9
    • Time Frame: After 9 months of treatment
  • Treatment tolerability
    • Time Frame: One year
    • Number and description of serious advent events
  • Treatment Impact on Quality of life
    • Time Frame: Before treatment initiation and after 12 months of treatment
    • Quality of life will be assessed before and at the end of the first year of treatment using a questionnaire given to patients. There is no questionnaire specifically tailored to vascular malformations in the literature. Thus the investigators adapted a document based on an evaluation of the quality of life for survivors of burn injury.

Participating in This Clinical Trial

Inclusion Criteria

  • Patients (adults, adolescents and children older than 2 years), with arteriovenous malformation stage II + III or IV (according to Schöbinger's classification) : active or quiescent, marked or not by hemorrhagic phenomena. – Patients (parents for minors) must sign a consent form established after clear information risks and expected benefits of the study. – Patients (major and minor of childbearing age) must have effective contraception during the study period and continuing until 12 weeks after the end of treatment – Negative pregnancy blood test for women of childbearing age. Exclusion Criteria:

  • Chronic or acquired immunosuppression : – patients with transplanted organ or who received a hematopoietic stem cell – patient with congenital immunodeficiency – Patients implanted with chronic active infection associated with hepatitis B , hepatitis C or HIV – Pregnant or nursing woman. – Allergy to macrolides – Allergy to peanut or soya – Hypersensitivity to " Sirolimus " or any of the excipients of the investigational product – Contraindications to performing an MRI – Leukopenia below 1 000 /mm3 – Thrombocytopenia lower to 80,000 /mm3 – Anemia with Hb < 9 g/dl – Elevated transaminase > 2.5 N – History of cancer less than two years before the inclusion – Surgery older than 2 months before inclusion – Active infection (viral and bacterial ) on the date of inclusion – Hypercholesterolemia > 7 mmol / l despite appropriate medical treatment – Hyperlipidemia > 2 mmol / l despite appropriate medical treatment – Uncontrolled diabetes – Patients unable to follow a clinical study – Major under guardianship, persons deprived of their liberty

Gender Eligibility: All

Minimum Age: 2 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Centre Hospitalier Universitaire, Amiens
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Bernard DEVAUCHELLE, MD, PhD, Study Director, CHU Amiens
    • Emmanuel MORELON, MD, PhD, Study Chair, HCL Lyon
  • Overall Contact(s)
    • Bernard DEVAUCHELLE, MD, PhD, +33322668325, devauchelle.bernard@chu-amiens.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.